脂肪间充质干细胞在系统性硬化症中的研究现状与展望

摘要

Mesenchymal/stromal stem cells (MSCs) are nonhematopoietic multipotent progenitor cells.More recently,the discovery of MSCs immunomodulatory,angiogenic and antifibrotic capabilities properties made MSCs-based therapy progressively slips from the field of regenerative medicine to autoimmunity.Adipose mesenchymal stem cells (ASCs) are MSCs derived from fat.In this article,we review the current research status of MSCs in systemic sclerosis (SSc,Scleroderma),and expound the feasibility of clinical application of ASCs in the treatment of SSc.%间充质干细胞(mesenchymal stromal/stem cells,MSCs)是一种非造血多能干细胞.最近,研究发现MSCs具有免疫调节、血管生成和抗纤维化的能力,从而使以MSCs为基础的干细胞应用逐渐从再生医学领域转向对自身免疫性疾病的治疗研究.脂肪间充质干细胞(adipose mesenchymal stem cells,ASCs)是来源于脂肪组织的MSCs.该文回顾当前MSCs在系统性硬化症(systemic sclerosis,SSc)中的研究现状,并展望临床应用ASCs治疗SSc的可行性.